With PALYNZIQ based on the positive pivotal data we announced in April, we are on track to submit applications in the second half of this year in the United States and Europe for the treatment of ...

Product revenues totaled $734.6 million, which rose 15% year over year on higher revenues from Voxzogo, Palynziq and Aldurazyme. This was partially offset by lower Kuvan sales. Royalty and other ...

The company is also focused on expanding the indications for PALYNZIQ and progressing BMN 351 and BMN 333 clinical programs. CFO Brian Mueller stated that VOXZOGO revenue grew 40% year-over-year ...

Biomarin Pharmaceutical Inc (BMRN) reports a robust 15% revenue increase and significant profitability expansion, while navigating global market dynamics and strategic investments.

BioMarin Pharmaceutical BMRN reported first-quarter 2025 adjusted earnings per share of $1.13, which beat the Zacks Consensus ...

There are a couple of drug treatments available, namely BioMarin’s enzyme-based therapies Kuvan (sapropterin) or Palynziq (pegvaliase), which are both approved to reduce levels of phe.